Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma

Summary

Penile squamous cell carcinoma (PSCC) is a highly aggressive and relatively rare disease. Supportive evidence for the value of systemic therapy does not exist for this disease and there are no agents currently approved by regulatory agencies. This study will evaluate the drug Gilotrif in patients with metastatic progressive PSCC following chemotherapy. Gilotrif has shown supportive evidence in non-small cell lung cancer by inhibiting certain proteins that are also found in PSCC. The drug has the potential for some patients to exhibit a response contributing to a greater quality of life.

Timeline

Start

2015-10

Primary completion

2019-01-26

Completion

2020-04

Outcome

Outcome not reported

Stopped (Enrollment): “poor overall accrual”

Drugs

Indications